At Skinovate Research, our commitment to safety is underscored by the Hypoallergenic Test, which offers consumers assurance of low allergy potential. This claim is especially appealing to those with sensitive skin, making it an essential component of our product appeal.
The Human Repeat Insult Patch Test (HRIPT) serves as a pivotal clinical assessment aimed at gauging the contact hypersensitivity and sensitization potential of cosmetic products. Spanning a duration of 41 days, this test encompasses three distinct phases meticulously designed to evaluate product safety.
Throughout the test, a controlled amount of the cosmetic product is applied to a patch, which is subsequently affixed to the skin of the test subject. The patch remains in place for a specified timeframe, during which the skin is closely monitored for any indications of irritation or inflammation. This process undergoes a total of 10 iterations during the induction phase, followed by a rest period of 14 days without application. The evaluation culminates in a 3-day challenge phase involving a single patch application.

The HRIPT method stands as a universally recognized approach for assessing the potential sensitization to contact hypersensitivity caused by cosmetic products. It’s a consistent and rigorous framework that empowers cosmetic companies to meticulously scrutinize their products for any potential consumer risks. By conducting the HRIPT, we reinforce our commitment to ensuring the utmost safety of our cosmetic offerings, safeguarding against any potential adverse reactions. This method serves as a pivotal tool in affirming that our cosmetic products are entirely safe, devoid of harm, and hypoallergenic, thus instilling confidence among consumers.